查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866643

肝素：全球市场份额和排名、总收入和需求预测（2025-2031 年）

Heparin - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球肝素市场规模估计为 12.25 亿美元，预计在 2025-2031 年预测期内将以 7.8% 的复合年增长率增长，到 2031 年将调整至 23.01 亿美元。

本报告对近期关税调整和国际战略反制措施对肝素跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组的影响进行了全面评估。

预计到2024年，全球肝素产量将达到约234980亿单位，全球平均市场价格约为每十亿单位52147美元。肝素是一种抗凝血剂（血液稀释药物），可防止血栓形成。它用于治疗和预防静脉、动脉或肺部血栓。此外，它也用于降低术前血栓形成的风险。大多数肝素产品以肝素钠或肝素钙的形式存在。本报告主要探讨肝素原料药（API）。

全球主要企业包括深圳海普林製药、烟台东城製药、南京金友生化製药、辉瑞和河北常山生化製药。前五大企业占了约54%的市场。中国在全球肝素市场占主导地位，产量比重超过65%。欧洲和亚太地区是两大市场，分别占约34%的市场份额，北美市场紧追在后，约占30%的市场份额。

肝素原料药市场的主要成长要素是全球心血管疾病和血栓性栓塞症发生率的上升，以及外科手术数量的增加。人口老化和肥胖率的上升也支撑了对抗凝血剂的持续需求。此外，肝素在治疗新冠肺炎相关血栓併发症的应用进一步推动了市场扩张。新兴市场（如中国和印度）製药业的发展以及生物製药领域对高品质肝素的需求也是推动市场成长的因素。

肝素原料药市场的主要趋势包括：1. 从动物源性肝素（猪肠粘膜提取物）向合成替代品（例如，低分子量肝素）的技术转型；2. 对供应链可追溯性和品管的严格监管要求；3. 生物类似药竞争加剧，推动工艺优化和成本降低；以及4. 由于新兴市场本土製药公司的崛起，全球肝素供应链呈现趋势。

本报告旨在对全球肝素市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名，还包括按地区/国家、类型和应用对肝素进行的分析。

肝素市场规模、估计值和预测以销售量（十亿）和收入（百万美元）为单位呈现，基准年为2024年，并包含2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定肝素业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Shenzhen Hepalink Pharmaceutical
  • Yantai Dongcheng Pharmaceutical
  • Pfizer
  • Bioiberica
  • Changzhou Qianhong Biopharma
  • Nanjing King-friend Biochemical Pharmaceutical
  • Hebei Changshan Biochemical Pharmaceutical
  • Qingdao Jiulong Biopharmaceutical
  • Opocrin
  • Dongying Tiandong Pharmaceutical
  • Aspen Oss
  • Yino Pharma
  • Nanjing Xinbai Pharmaceutical
  • Hubei Enoray Biopharmaceutical
  • Cisen Pharmaceutical

按类型分類的细分市场

  • 肝素钠
  • 肝素钙

应用领域

  • UFH
  • 低分子量肝素

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Heparin was estimated to be worth US$ 1225 million in 2024 and is forecast to a readjusted size of US$ 2301 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Heparin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

In 2024, global Heparin production reached approximately 23,498 billion units , with an average global market price of around US$ 52,147 per billion units. Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the Heparin API.

Global key players of Heparin include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, etc. The top five manufacturers hold a share about 54%. China is dominating the global Heparin market, has a share over 65% in terms of production. Europe and Asia-Pacific are the two largest market, both having a share about 34%, followed by North America, with a share about 30 percent.

The heparin API market is primarily driven by the rising global prevalence of cardiovascular and thromboembolic diseases, along with increasing surgical procedures. Growing aging populations and higher obesity rates contribute to sustained demand for anticoagulants. Additionally, heparin's use in treating COVID-19-associated thrombotic complications has further propelled market expansion. Pharmaceutical industry advancements in emerging markets (e.g., China and India) and the biopharmaceutical sector's demand for high-quality heparin also fuel market growth.

Key trends in the heparin API market include: 1) a technological shift from animal-sourced heparin (porcine intestinal mucosa extraction) to synthetic alternatives (e.g., low-molecular-weight heparin); 2) stringent regulatory requirements for supply chain traceability and quality control; 3) intensified competition from biosimilars, driving process optimization and cost reduction; and 4) the rise of local pharmaceutical players in emerging markets, diversifying the global heparin supply chain.

This report aims to provide a comprehensive presentation of the global market for Heparin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Heparin by region & country, by Type, and by Application.

The Heparin market size, estimations, and forecasts are provided in terms of sales volume (billion units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heparin.

Market Segmentation

By Company

  • Shenzhen Hepalink Pharmaceutical
  • Yantai Dongcheng Pharmaceutical
  • Pfizer
  • Bioiberica
  • Changzhou Qianhong Biopharma
  • Nanjing King-friend Biochemical Pharmaceutical
  • Hebei Changshan Biochemical Pharmaceutical
  • Qingdao Jiulong Biopharmaceutical
  • Opocrin
  • Dongying Tiandong Pharmaceutical
  • Aspen Oss
  • Yino Pharma
  • Nanjing Xinbai Pharmaceutical
  • Hubei Enoray Biopharmaceutical
  • Cisen Pharmaceutical

Segment by Type

  • Heparin Sodium
  • Heparin Calcium

Segment by Application

  • UFH
  • LMWH

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Heparin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Heparin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Heparin in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Heparin Product Introduction
  • 1.2 Global Heparin Market Size Forecast
    • 1.2.1 Global Heparin Sales Value (2020-2031)
    • 1.2.2 Global Heparin Sales Volume (2020-2031)
    • 1.2.3 Global Heparin Sales Price (2020-2031)
  • 1.3 Heparin Market Trends & Drivers
    • 1.3.1 Heparin Industry Trends
    • 1.3.2 Heparin Market Drivers & Opportunity
    • 1.3.3 Heparin Market Challenges
    • 1.3.4 Heparin Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Heparin Players Revenue Ranking (2024)
  • 2.2 Global Heparin Revenue by Company (2020-2025)
  • 2.3 Global Heparin Players Sales Volume Ranking (2024)
  • 2.4 Global Heparin Sales Volume by Company Players (2020-2025)
  • 2.5 Global Heparin Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Heparin Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Heparin Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Heparin
  • 2.9 Heparin Market Competitive Analysis
    • 2.9.1 Heparin Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Heparin Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Heparin as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Heparin Sodium
    • 3.1.2 Heparin Calcium
  • 3.2 Global Heparin Sales Value by Type
    • 3.2.1 Global Heparin Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Heparin Sales Value, by Type (2020-2031)
    • 3.2.3 Global Heparin Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Heparin Sales Volume by Type
    • 3.3.1 Global Heparin Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Heparin Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Heparin Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Heparin Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 UFH
    • 4.1.2 LMWH
  • 4.2 Global Heparin Sales Value by Application
    • 4.2.1 Global Heparin Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Heparin Sales Value, by Application (2020-2031)
    • 4.2.3 Global Heparin Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Heparin Sales Volume by Application
    • 4.3.1 Global Heparin Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Heparin Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Heparin Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Heparin Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Heparin Sales Value by Region
    • 5.1.1 Global Heparin Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Heparin Sales Value by Region (2020-2025)
    • 5.1.3 Global Heparin Sales Value by Region (2026-2031)
    • 5.1.4 Global Heparin Sales Value by Region (%), (2020-2031)
  • 5.2 Global Heparin Sales Volume by Region
    • 5.2.1 Global Heparin Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Heparin Sales Volume by Region (2020-2025)
    • 5.2.3 Global Heparin Sales Volume by Region (2026-2031)
    • 5.2.4 Global Heparin Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Heparin Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Heparin Sales Value, 2020-2031
    • 5.4.2 North America Heparin Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Heparin Sales Value, 2020-2031
    • 5.5.2 Europe Heparin Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Heparin Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Heparin Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Heparin Sales Value, 2020-2031
    • 5.7.2 South America Heparin Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Heparin Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Heparin Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Heparin Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Heparin Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Heparin Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Heparin Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Heparin Sales Value, 2020-2031
    • 6.3.2 United States Heparin Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Heparin Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Heparin Sales Value, 2020-2031
    • 6.4.2 Europe Heparin Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Heparin Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Heparin Sales Value, 2020-2031
    • 6.5.2 China Heparin Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Heparin Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Heparin Sales Value, 2020-2031
    • 6.6.2 Japan Heparin Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Heparin Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Heparin Sales Value, 2020-2031
    • 6.7.2 South Korea Heparin Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Heparin Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Heparin Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Heparin Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Heparin Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Heparin Sales Value, 2020-2031
    • 6.9.2 India Heparin Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Heparin Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Shenzhen Hepalink Pharmaceutical
    • 7.1.1 Shenzhen Hepalink Pharmaceutical Company Information
    • 7.1.2 Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
    • 7.1.3 Shenzhen Hepalink Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Shenzhen Hepalink Pharmaceutical Heparin Product Offerings
    • 7.1.5 Shenzhen Hepalink Pharmaceutical Recent Development
  • 7.2 Yantai Dongcheng Pharmaceutical
    • 7.2.1 Yantai Dongcheng Pharmaceutical Company Information
    • 7.2.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
    • 7.2.3 Yantai Dongcheng Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Yantai Dongcheng Pharmaceutical Heparin Product Offerings
    • 7.2.5 Yantai Dongcheng Pharmaceutical Recent Development
  • 7.3 Pfizer
    • 7.3.1 Pfizer Company Information
    • 7.3.2 Pfizer Introduction and Business Overview
    • 7.3.3 Pfizer Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Pfizer Heparin Product Offerings
    • 7.3.5 Pfizer Recent Development
  • 7.4 Bioiberica
    • 7.4.1 Bioiberica Company Information
    • 7.4.2 Bioiberica Introduction and Business Overview
    • 7.4.3 Bioiberica Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Bioiberica Heparin Product Offerings
    • 7.4.5 Bioiberica Recent Development
  • 7.5 Changzhou Qianhong Biopharma
    • 7.5.1 Changzhou Qianhong Biopharma Company Information
    • 7.5.2 Changzhou Qianhong Biopharma Introduction and Business Overview
    • 7.5.3 Changzhou Qianhong Biopharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Changzhou Qianhong Biopharma Heparin Product Offerings
    • 7.5.5 Changzhou Qianhong Biopharma Recent Development
  • 7.6 Nanjing King-friend Biochemical Pharmaceutical
    • 7.6.1 Nanjing King-friend Biochemical Pharmaceutical Company Information
    • 7.6.2 Nanjing King-friend Biochemical Pharmaceutical Introduction and Business Overview
    • 7.6.3 Nanjing King-friend Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Nanjing King-friend Biochemical Pharmaceutical Heparin Product Offerings
    • 7.6.5 Nanjing King-friend Biochemical Pharmaceutical Recent Development
  • 7.7 Hebei Changshan Biochemical Pharmaceutical
    • 7.7.1 Hebei Changshan Biochemical Pharmaceutical Company Information
    • 7.7.2 Hebei Changshan Biochemical Pharmaceutical Introduction and Business Overview
    • 7.7.3 Hebei Changshan Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Hebei Changshan Biochemical Pharmaceutical Heparin Product Offerings
    • 7.7.5 Hebei Changshan Biochemical Pharmaceutical Recent Development
  • 7.8 Qingdao Jiulong Biopharmaceutical
    • 7.8.1 Qingdao Jiulong Biopharmaceutical Company Information
    • 7.8.2 Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
    • 7.8.3 Qingdao Jiulong Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Qingdao Jiulong Biopharmaceutical Heparin Product Offerings
    • 7.8.5 Qingdao Jiulong Biopharmaceutical Recent Development
  • 7.9 Opocrin
    • 7.9.1 Opocrin Company Information
    • 7.9.2 Opocrin Introduction and Business Overview
    • 7.9.3 Opocrin Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Opocrin Heparin Product Offerings
    • 7.9.5 Opocrin Recent Development
  • 7.10 Dongying Tiandong Pharmaceutical
    • 7.10.1 Dongying Tiandong Pharmaceutical Company Information
    • 7.10.2 Dongying Tiandong Pharmaceutical Introduction and Business Overview
    • 7.10.3 Dongying Tiandong Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Dongying Tiandong Pharmaceutical Heparin Product Offerings
    • 7.10.5 Dongying Tiandong Pharmaceutical Recent Development
  • 7.11 Aspen Oss
    • 7.11.1 Aspen Oss Company Information
    • 7.11.2 Aspen Oss Introduction and Business Overview
    • 7.11.3 Aspen Oss Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Aspen Oss Heparin Product Offerings
    • 7.11.5 Aspen Oss Recent Development
  • 7.12 Yino Pharma
    • 7.12.1 Yino Pharma Company Information
    • 7.12.2 Yino Pharma Introduction and Business Overview
    • 7.12.3 Yino Pharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 Yino Pharma Heparin Product Offerings
    • 7.12.5 Yino Pharma Recent Development
  • 7.13 Nanjing Xinbai Pharmaceutical
    • 7.13.1 Nanjing Xinbai Pharmaceutical Company Information
    • 7.13.2 Nanjing Xinbai Pharmaceutical Introduction and Business Overview
    • 7.13.3 Nanjing Xinbai Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 Nanjing Xinbai Pharmaceutical Heparin Product Offerings
    • 7.13.5 Nanjing Xinbai Pharmaceutical Recent Development
  • 7.14 Hubei Enoray Biopharmaceutical
    • 7.14.1 Hubei Enoray Biopharmaceutical Company Information
    • 7.14.2 Hubei Enoray Biopharmaceutical Introduction and Business Overview
    • 7.14.3 Hubei Enoray Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.14.4 Hubei Enoray Biopharmaceutical Heparin Product Offerings
    • 7.14.5 Hubei Enoray Biopharmaceutical Recent Development
  • 7.15 Cisen Pharmaceutical
    • 7.15.1 Cisen Pharmaceutical Company Information
    • 7.15.2 Cisen Pharmaceutical Introduction and Business Overview
    • 7.15.3 Cisen Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.15.4 Cisen Pharmaceutical Heparin Product Offerings
    • 7.15.5 Cisen Pharmaceutical Recent Development

8 Industry Chain Analysis

  • 8.1 Heparin Industrial Chain
  • 8.2 Heparin Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Heparin Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Heparin Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Heparin Market Trends
  • Table 2. Heparin Market Drivers & Opportunity
  • Table 3. Heparin Market Challenges
  • Table 4. Heparin Market Restraints
  • Table 5. Global Heparin Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Heparin Revenue Market Share by Company (2020-2025)
  • Table 7. Global Heparin Sales Volume by Company (2020-2025) & (billion units)
  • Table 8. Global Heparin Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Heparin Price by Company (2020-2025) & (US$/billion units)
  • Table 10. Key Manufacturers Heparin Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Heparin Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Heparin
  • Table 13. Global Heparin Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Heparin as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Heparin Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Heparin Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Heparin Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Heparin Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Heparin Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Heparin Sales Volume by Type: 2020 VS 2024 VS 2031 (billion units)
  • Table 22. Global Heparin Sales Volume by Type (2020-2025) & (billion units)
  • Table 23. Global Heparin Sales Volume by Type (2026-2031) & (billion units)
  • Table 24. Global Heparin Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Heparin Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Heparin Price by Type (2020-2025) & (US$/billion units)
  • Table 27. Global Heparin Price by Type (2026-2031) & (US$/billion units)
  • Table 28. Global Heparin Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Heparin Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Heparin Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Heparin Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Heparin Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Heparin Sales Volume by Application: 2020 VS 2024 VS 2031 (billion units)
  • Table 34. Global Heparin Sales Volume by Application (2020-2025) & (billion units)
  • Table 35. Global Heparin Sales Volume by Application (2026-2031) & (billion units)
  • Table 36. Global Heparin Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Heparin Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Heparin Price by Application (2020-2025) & (US$/billion units)
  • Table 39. Global Heparin Price by Application (2026-2031) & (US$/billion units)
  • Table 40. Global Heparin Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Heparin Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Heparin Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Heparin Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Heparin Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Heparin Sales Volume by Region (billion units): 2020 VS 2024 VS 2031
  • Table 46. Global Heparin Sales Volume by Region (2020-2025) & (billion units)
  • Table 47. Global Heparin Sales Volume by Region (2026-2031) & (billion units)
  • Table 48. Global Heparin Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Heparin Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Heparin Average Price by Region (2020-2025) & (US$/billion units)
  • Table 51. Global Heparin Average Price by Region (2026-2031) & (US$/billion units)
  • Table 52. Key Countries/Regions Heparin Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Heparin Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Heparin Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Heparin Sales Volume, (2020-2025) & (billion units)
  • Table 56. Key Countries/Regions Heparin Sales Volume, (2026-2031) & (billion units)
  • Table 57. Shenzhen Hepalink Pharmaceutical Company Information
  • Table 58. Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
  • Table 59. Shenzhen Hepalink Pharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 60. Shenzhen Hepalink Pharmaceutical Heparin Product Offerings
  • Table 61. Shenzhen Hepalink Pharmaceutical Recent Development
  • Table 62. Yantai Dongcheng Pharmaceutical Company Information
  • Table 63. Yantai Dongcheng Pharmaceutical Introduction and Business Overview
  • Table 64. Yantai Dongcheng Pharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 65. Yantai Dongcheng Pharmaceutical Heparin Product Offerings
  • Table 66. Yantai Dongcheng Pharmaceutical Recent Development
  • Table 67. Pfizer Company Information
  • Table 68. Pfizer Introduction and Business Overview
  • Table 69. Pfizer Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 70. Pfizer Heparin Product Offerings
  • Table 71. Pfizer Recent Development
  • Table 72. Bioiberica Company Information
  • Table 73. Bioiberica Introduction and Business Overview
  • Table 74. Bioiberica Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 75. Bioiberica Heparin Product Offerings
  • Table 76. Bioiberica Recent Development
  • Table 77. Changzhou Qianhong Biopharma Company Information
  • Table 78. Changzhou Qianhong Biopharma Introduction and Business Overview
  • Table 79. Changzhou Qianhong Biopharma Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 80. Changzhou Qianhong Biopharma Heparin Product Offerings
  • Table 81. Changzhou Qianhong Biopharma Recent Development
  • Table 82. Nanjing King-friend Biochemical Pharmaceutical Company Information
  • Table 83. Nanjing King-friend Biochemical Pharmaceutical Introduction and Business Overview
  • Table 84. Nanjing King-friend Biochemical Pharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 85. Nanjing King-friend Biochemical Pharmaceutical Heparin Product Offerings
  • Table 86. Nanjing King-friend Biochemical Pharmaceutical Recent Development
  • Table 87. Hebei Changshan Biochemical Pharmaceutical Company Information
  • Table 88. Hebei Changshan Biochemical Pharmaceutical Introduction and Business Overview
  • Table 89. Hebei Changshan Biochemical Pharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 90. Hebei Changshan Biochemical Pharmaceutical Heparin Product Offerings
  • Table 91. Hebei Changshan Biochemical Pharmaceutical Recent Development
  • Table 92. Qingdao Jiulong Biopharmaceutical Company Information
  • Table 93. Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
  • Table 94. Qingdao Jiulong Biopharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 95. Qingdao Jiulong Biopharmaceutical Heparin Product Offerings
  • Table 96. Qingdao Jiulong Biopharmaceutical Recent Development
  • Table 97. Opocrin Company Information
  • Table 98. Opocrin Introduction and Business Overview
  • Table 99. Opocrin Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 100. Opocrin Heparin Product Offerings
  • Table 101. Opocrin Recent Development
  • Table 102. Dongying Tiandong Pharmaceutical Company Information
  • Table 103. Dongying Tiandong Pharmaceutical Introduction and Business Overview
  • Table 104. Dongying Tiandong Pharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 105. Dongying Tiandong Pharmaceutical Heparin Product Offerings
  • Table 106. Dongying Tiandong Pharmaceutical Recent Development
  • Table 107. Aspen Oss Company Information
  • Table 108. Aspen Oss Introduction and Business Overview
  • Table 109. Aspen Oss Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 110. Aspen Oss Heparin Product Offerings
  • Table 111. Aspen Oss Recent Development
  • Table 112. Yino Pharma Company Information
  • Table 113. Yino Pharma Introduction and Business Overview
  • Table 114. Yino Pharma Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 115. Yino Pharma Heparin Product Offerings
  • Table 116. Yino Pharma Recent Development
  • Table 117. Nanjing Xinbai Pharmaceutical Company Information
  • Table 118. Nanjing Xinbai Pharmaceutical Introduction and Business Overview
  • Table 119. Nanjing Xinbai Pharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 120. Nanjing Xinbai Pharmaceutical Heparin Product Offerings
  • Table 121. Nanjing Xinbai Pharmaceutical Recent Development
  • Table 122. Hubei Enoray Biopharmaceutical Company Information
  • Table 123. Hubei Enoray Biopharmaceutical Introduction and Business Overview
  • Table 124. Hubei Enoray Biopharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 125. Hubei Enoray Biopharmaceutical Heparin Product Offerings
  • Table 126. Hubei Enoray Biopharmaceutical Recent Development
  • Table 127. Cisen Pharmaceutical Company Information
  • Table 128. Cisen Pharmaceutical Introduction and Business Overview
  • Table 129. Cisen Pharmaceutical Heparin Sales (billion units), Revenue (US$ Million), Price (US$/billion units) and Gross Margin (2020-2025)
  • Table 130. Cisen Pharmaceutical Heparin Product Offerings
  • Table 131. Cisen Pharmaceutical Recent Development
  • Table 132. Key Raw Materials Lists
  • Table 133. Raw Materials Key Suppliers Lists
  • Table 134. Heparin Downstream Customers
  • Table 135. Heparin Distributors List
  • Table 136. Research Programs/Design for This Report
  • Table 137. Key Data Information from Secondary Sources
  • Table 138. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Heparin Product Picture
  • Figure 2. Global Heparin Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Heparin Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Heparin Sales Volume (2020-2031) & (billion units)
  • Figure 5. Global Heparin Sales Price (2020-2031) & (US$/billion units)
  • Figure 6. Heparin Report Years Considered
  • Figure 7. Global Heparin Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Heparin Players Sales Volume Ranking (2024) & (billion units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Heparin Revenue in 2024
  • Figure 10. Heparin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Heparin Sodium Picture
  • Figure 12. Heparin Calcium Picture
  • Figure 13. Global Heparin Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Heparin Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Heparin Sales Volume by Type (2020 VS 2024 VS 2031) & (billion units)
  • Figure 16. Global Heparin Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Heparin Price by Type (2020-2031) & (US$/billion units)
  • Figure 18. Product Picture of UFH
  • Figure 19. Product Picture of LMWH
  • Figure 20. Global Heparin Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Heparin Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. Global Heparin Sales Volume by Application (2020 VS 2024 VS 2031) & (billion units)
  • Figure 23. Global Heparin Sales Volume Market Share by Application, 2024 & 2031
  • Figure 24. Global Heparin Price by Application (2020-2031) & (US$/billion units)
  • Figure 25. North America Heparin Sales Value (2020-2031) & (US$ Million)
  • Figure 26. North America Heparin Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Europe Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Europe Heparin Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Asia Pacific Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Asia Pacific Heparin Sales Value by Region (%), 2024 VS 2031
  • Figure 31. South America Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. South America Heparin Sales Value by Country (%), 2024 VS 2031
  • Figure 33. Middle East & Africa Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Middle East & Africa Heparin Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Key Countries/Regions Heparin Sales Value (%), (2020-2031)
  • Figure 36. Key Countries/Regions Heparin Sales Volume (%), (2020-2031)
  • Figure 37. United States Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. United States Heparin Sales Value by Type (%), 2024 VS 2031
  • Figure 39. United States Heparin Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Europe Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Europe Heparin Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Europe Heparin Sales Value by Application (%), 2024 VS 2031
  • Figure 43. China Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. China Heparin Sales Value by Type (%), 2024 VS 2031
  • Figure 45. China Heparin Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Japan Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Japan Heparin Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Japan Heparin Sales Value by Application (%), 2024 VS 2031
  • Figure 49. South Korea Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. South Korea Heparin Sales Value by Type (%), 2024 VS 2031
  • Figure 51. South Korea Heparin Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Southeast Asia Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. Southeast Asia Heparin Sales Value by Type (%), 2024 VS 2031
  • Figure 54. Southeast Asia Heparin Sales Value by Application (%), 2024 VS 2031
  • Figure 55. India Heparin Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. India Heparin Sales Value by Type (%), 2024 VS 2031
  • Figure 57. India Heparin Sales Value by Application (%), 2024 VS 2031
  • Figure 58. Heparin Industrial Chain
  • Figure 59. Heparin Manufacturing Cost Structure
  • Figure 60. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 61. Bottom-up and Top-down Approaches for This Report
  • Figure 62. Data Triangulation
  • Figure 63. Key Executives Interviewed